医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
17期
31-32
,共2页
腹泻型肠易激综合征%马来酸曲美布汀%蒙脱石散%疗效
腹瀉型腸易激綜閤徵%馬來痠麯美佈汀%矇脫石散%療效
복사형장역격종합정%마래산곡미포정%몽탈석산%료효
diarrhea-predominant%irritable bowel syndrome%maleate Trimebutine%montmoril onite powder efficacy
目的：分析探讨腹泻型肠易激综合征采用马来酸曲美布汀联合蒙脱石散治疗的临床疗效。方法：选取我院近年来收治的96例腹泻型肠易激综合征患者作为研究对象，按照患者就诊顺序编号将其随机分为研究组与对照组，每组48例，对照组患者仅给予马来酸曲美布汀治疗，研究组患者行马来酸曲美布汀联合蒙脱石散治疗，比较两组治疗效果。结果：对照组患者治疗显效率为31.3%，总有效率为70.9%，研究组患者治疗显效率为52.0%，总有效率为91.7%，研究组患者治疗效果明显优于对照组(P<0.05)。研究组患者治疗过程中不良反应发生率为10.4%，对照组不良反应发生率为8.3%，未出现严重的不良反应。两组在不良反应发生率方面比较无显著差异( P>0.05)，无统计学意义。结论：腹泻型肠易激综合征行马来酸曲美布汀联合蒙脱石散治疗具有显著的临床疗效，值得推广应用。
目的：分析探討腹瀉型腸易激綜閤徵採用馬來痠麯美佈汀聯閤矇脫石散治療的臨床療效。方法：選取我院近年來收治的96例腹瀉型腸易激綜閤徵患者作為研究對象，按照患者就診順序編號將其隨機分為研究組與對照組，每組48例，對照組患者僅給予馬來痠麯美佈汀治療，研究組患者行馬來痠麯美佈汀聯閤矇脫石散治療，比較兩組治療效果。結果：對照組患者治療顯效率為31.3%，總有效率為70.9%，研究組患者治療顯效率為52.0%，總有效率為91.7%，研究組患者治療效果明顯優于對照組(P<0.05)。研究組患者治療過程中不良反應髮生率為10.4%，對照組不良反應髮生率為8.3%，未齣現嚴重的不良反應。兩組在不良反應髮生率方麵比較無顯著差異( P>0.05)，無統計學意義。結論：腹瀉型腸易激綜閤徵行馬來痠麯美佈汀聯閤矇脫石散治療具有顯著的臨床療效，值得推廣應用。
목적：분석탐토복사형장역격종합정채용마래산곡미포정연합몽탈석산치료적림상료효。방법：선취아원근년래수치적96례복사형장역격종합정환자작위연구대상，안조환자취진순서편호장기수궤분위연구조여대조조，매조48례，대조조환자부급여마래산곡미포정치료，연구조환자행마래산곡미포정연합몽탈석산치료，비교량조치료효과。결과：대조조환자치료현효솔위31.3%，총유효솔위70.9%，연구조환자치료현효솔위52.0%，총유효솔위91.7%，연구조환자치료효과명현우우대조조(P<0.05)。연구조환자치료과정중불량반응발생솔위10.4%，대조조불량반응발생솔위8.3%，미출현엄중적불량반응。량조재불량반응발생솔방면비교무현저차이( P>0.05)，무통계학의의。결론：복사형장역격종합정행마래산곡미포정연합몽탈석산치료구유현저적림상료효，치득추엄응용。
Objective: To investigate the diarrhea -predominant irritable bowel syndrome using clinical efficacy maleate Trimebutine montmoril onite powder combined therapy . Methods: In recent years, the hospital treated 96 patients with diarrhea -predominant irritable bowel syndrome patients as research subjects , according to the treatment of patients sequential y numbered randomly divided into study group and the control group , patients in the control group of 48 patients in each group given only horse to trimebutine treatment, the study group patients maleate trimebutine montmoril onite powder combined therapy, therapeutic effects were compared . Results: The effective rate of the treatment of patients in the control group and 31.3%of the total effective rate was 70.9% , the study group was 52.0% of patients markedly , the total effective rate was 91.7 %, the treatment effect of the study group were significantly better than the control group (P <0.05 ) . Patients in the study group during the treatment of adverse reactions was 10.4% , occurred in the control group was 8.3%of adverse reactions , serious adverse reactions occur . Showed no significant difference (P> 0.05) in the incidence of adverse events was not statistical y significant. Conclusion: diarrhea-predominant irritable bowel syndrome line maleate Trimebutine montmoril onite powder combined therapy with significant clinical effect , should be widely applied .
